| Bio Roundup: MESO’s Miss, Pfizer’s Cancer Bet, Vaccine Promise & More | Frank Vinluan | 10/02/20 | National |
| Two Days, Six IPOs, and $1B Raised for Biotech Research & More | Frank Vinluan | 07/17/20 | National |
| Viacyte Adds $27M to Move Ahead Trio of Stem Cell Diabetes Treatments | Sarah de Crescenzo | 05/26/20 | San Diego |
| Bio Roundup: Clinical Trials Paused, New MS Drug, Kallyope’s Cash & More | Frank Vinluan | 03/27/20 | National |
| FDA Rejects Boehringer Ingelheim, Eli Lilly Drug for Type 1 Diabetes | Frank Vinluan | 03/23/20 | Europe |
| Bio Roundup: Mammoth Moves, Black Diamond’s Pop, Ohana’s Debut & More | Frank Vinluan | 01/31/20 | National |
| PanTheryx Lands $50M to Use “First Milk” to Target Gut Microbiome | Frank Vinluan | 06/26/19 | Boulder/Denver |
| Bio Roundup: Opioids in Court, IPO Parade, Brain Cancer Bet & More | Frank Vinluan | 05/31/19 | National |
| NGM Bio’s IPO Raises $107M as NASH Drug Continues Clinical Testing | Frank Vinluan | 04/03/19 | San Francisco |
| Bio Roundup: Gottlieb Exits, Bristol Defends, Biogen Buys & More | Alex Lash | 03/08/19 | National |
| ViaCyte Raises $80M to Prep for the Clinic Now, Perhaps an IPO Later | Sarah de Crescenzo | 11/29/18 | San Diego |
| FDA Halts Clinical Test of Zafgen Diabetes Drug, Stock Price Tumbles | Frank Vinluan | 11/26/18 | Boston |
| With $59M, Casma and Ex-Constellation CEO Take Aim at Cellular Trash | Ben Fidler | 05/03/18 | Boston |
| Virta Health Hauls in $45M to Expand “Diabetes-Reversing” Software | Frank Vinluan | 04/04/18 | San Francisco |
| Bio Roundup: Biotech IPOs, Migraine Progress, Takeda Woos Shire & More | Frank Vinluan | 03/30/18 | National |
| Bio Roundup: Frazier v. Trump, Data Dumps, New York Steps & More | Ben Fidler | 08/18/17 | National |
| Novo Nordisk Diabetes Drug Beats Lilly’s Trulicity in Head-to-Head Test | Frank Vinluan | 08/17/17 | Indiana |
| With $23M, Flagship-Backed Sigilon Protects Protein-Producing Cells | David Holley | 06/21/17 | Boston |
| With Gene Therapy for Diabetes, San Antonio Researcher Eyes Funding | David Holley | 05/31/17 | Texas |
| Future At Stake, Zafgen Gives First Glimpse of New Obesity Drug Data | Ben Fidler | 05/04/17 | Boston |
| Some See Large EHR Vendors as Playing Catch-up in Population Health | Jeff Buchanan | 05/03/17 | Wisconsin |
| ViaCyte Working with Gore to Improve its Synthetic Pancreas Device | Bruce V. Bigelow | 03/29/17 | San Diego |
| Backed by $37M, Virta Tries Tech Approach to “Reverse” Diabetes | Frank Vinluan | 03/08/17 | San Francisco |
| Gates Foundation Sends $140M to Intarcia for HIV Version of Pump | David Holley | 12/29/16 | Boston |
| Diabetes Study, Hiring News, Growth Mileposts, & More Local Tech News | Sarah Schmid Stevenson | 12/27/16 | Indiana |
| Sanofi, Verily Fund Diabetes Startup With $500M | Alex Lash | 09/12/16 | Boston |
| After Shift to Duchenne and Cholesterol Drugs, Catabasis Files For IPO | Ben Fidler | 05/14/15 | Boston |
| Intarcia, Still Private, Nabs $225M More For Diabetes Device | Ben Fidler | 04/28/15 | Boston |
| Xbiotech’s $76M Offering Sets Course for Late-Stage Cancer Studies | David Holley | 04/15/15 | Texas |
| Gelesis Bags $22M More, Ramps Up Trials for Weight-Loss Pill | Ben Fidler | 03/26/15 | Boston |
